Atlas Venture plans a biotech-only future via VC mitosis

For the past 35 years, Atlas Venture has operated as a diversified investor, splitting its efforts between technology and life sciences. Starting next year, the two sides will part, with the biotech team retaining the Atlas name and setting out on its own fundraising mission, while the IT group will do the same under a to-be-determined moniker. The division has been long in the making, partner Bruce Booth writes, and Atlas believes its biotech operation is poised to thrive on its own, pointing to a string of recent exits including Zafgen ($ZFGN), Costim Pharmaceuticals and Avila Therapeutics. More

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.